The 12 years old male patient presented here suffers from neuronal ceroid lipofuscinoses 2 (CLN2) (MIM# 204500) and receives intracerebroventricular enzyme replacement therapy (ICV-ERT) every 14 days. After the emergence of the coronavirus disease 2019 (COVID-19) pandemic, routine care of children and adolescents with rare chronic diseases has become challenging. Although, in general, children do not develop severe COVID-19, when severe acute respiratory syndrome coronavirus 2infection was detected by polymerase chain reaction-screening examination in our CLN2 patient before hospital admission for ICV-ERT, he was regarded to be at risk. Upon diagnosis, the patient developed respiratory deterioration symptoms and was admitted to our pediatric intensive care unit to receive oxygen, remdesivir, and steroids. As far as we know, this is the first CLN2 patient receiving intraventricular enzyme therapy with COVID-19 who required intensive care treatment and specific therapy.

这里介绍的 12 岁男性患者患有神经元蜡样脂褐质 2 (CLN2) (MIM# 204500)，每 14 天接受一次脑室内酶替代疗法 (ICV-ERT)。在 2019 年冠状病毒病 (COVID-19) 大流行出现后，对患有罕见慢性病的儿童和青少年的常规护理变得具有挑战性。虽然一般来说，儿童不会发展为严重的 COVID-19，但当我们的 CLN2 患者在因 ICV-ERT 入院前通过聚合酶链反应筛查检查检测到严重急性呼吸综合征冠状病毒 2 感染时，他被认为处于危险之中。诊断后，患者出现呼吸恶化症状，并被送入我们的儿科重症监护室接受氧气、瑞德西韦和类固醇治疗。据我们了解，